Novo Nordisk and the Chinese Academy of Sciences establish

ResearchFoundation in China

2007-4-3

Novo Nordisk and the Chinese Academy of Sciences (CAS) signed an agreement on April 3^rd, 2007, that establishes a joint research foundation in China. The aim of Novo Nordisk-Chinese Academy of Science Research Foundation (NN-CAS Foundation) is to fund or co-fund activities of common interest within the fields of diabetes and biopharmaceuticals including related disciplines and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology, endocrinology and drug delivery. The Foundation supports projects of interests to both CAS and NN (including PhD and Post Doc fellowships).

“We look forward to a fruitful cooperation with Novo Nordisk,” says Professor Zhu Chen, former CAS Vice President and Chair Person of the NN-CAS Foundation. “Chinese and Danish scientists share a history of excellent collaborations which the new foundation will further strengthen. Novo Nordisk is well recognized in China for its major role in preventing and treating diabetes. We are very pleased to collaborate with Novo Nordisk and believe the collaboration will be of great benefit to both parties.”

In January 2002, Novo Nordisk established a world class R&D centre in Beijing, which is the first R&D centre in China established by international bio-pharmaceutical companies. After five years of R&D activities in China, Novo Nordisk decided to cooperate with CAS and fund 2,000,000 US dollars in supporting research in diabetes and biopharmaceuticals.

“This cooperation illustrates the great attention Novo Nordisk pays to China as well as our long-term commitment to help in further developing the Chinese healthcare system” says Dr. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. He also emphasized that Novo Nordisk will continue to launch new products in China and increase the company’s R&D presence in the country.